Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.

Date publication

janvier 2017

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa

Tous les auteurs :
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27914243

Résumé

To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma.

Référence

Eur. J. Cancer. 2017 Jan;70:133-142